Coya Therapeutics Incに関するコメント

$Coya Therapeutics Inc(COYA.US)$
NEWS
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Serum 4-HNE levels in ALS patients correlate with disease progression and survival, with higher levels indicating faster progression and shorter survival. The ROC analysis shows 100% sensitivity for a 21-month survival threshold, making it a potential biomarker for ALS. The presentation at the Johnson Center Symposium highlighted the predictive value of 4-HNE in as...

$Coya Therapeutics Inc(COYA.US)$ Coya Therapeutics Licenses IP Rights For Immune Modulatory Biologics In Combination With COYA 301 To Enhance Regulatory T Cells In Inflammatory Diseases
Benzinga· 1 min ago

$Coya Therapeutics Inc(COYA.US)$ Coya Therapeutics Announces Pipeline Expansion Of COYA 302 To Include Frontotemporal Dementia and Parkinson's Disease
Benzinga· 3 mins ago

$Coya Therapeutics Inc(COYA.US)$ Coya Therapeutics Reveals Successful Pre-IND And Type C Meetings With FDA To Advance Development Of COYA 302 For Treatment Of Amyotrophic Lateral Sclerosis (ALS)
Benzinga· 5 mins ago

$Coya Therapeutics Inc(COYA.US)$ Dr. Reddy's To Make $7.5M Upfront Payment To Coya, $4.2M Payment Upon Acceptance Of IND Application, $4.2M Upon First Patient Dosing And Development And Regulatory Milestones Of Up To $40M; Coya Is Eligible For Up To $677.25M In Sales-Based Milestones

$Coya Therapeutics Inc(COYA.US)$ Coya Therapeutics Announces $26.5 Million Private Placement

$Coya Therapeutics Inc(COYA.US)$Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)

$Coya Therapeutics Inc(COYA.US)$ keep buying. need to get over $4.50